30652-11-0Relevant articles and documents
Dissociation of CP20 from iron(II)(cp20)3: A pulse radiolysis study
Merkofer, Martin,Domazou, Anastasia,Nauser, Thomas,Koppenol, Willem H.
, p. 671 - 675 (2006)
Deferiprone (CP20), a hydroxypyridine-4-one, is used in iron-chelation therapy. For the iron(III)-/(II)(cp20)3 couple, a standard electrode potential of -620 mV was measured by cyclic voltammetry [Templeton et al., Inorg. Chim. Acta 1996, 245, 199; Merkofer et al., Helv. Chim. Acta 2004, 87, 3021]. On the basis of this value and the overall stability constant for the equilibrium of iron(III) and three CP20 molecules, ligand dissociation ought to take place after reduction of the iron(III)(cp20)3 complex. By pulse radiolysis, we show that hydrated electrons reduce the iron(III)(cp20) 3 complex with a rate constant of k = (6.4 ± 0.3) × 1010 M-1S-1, and that the iron(II)(cp20) 3 complex aquates rapidly. The dissociation of the first two CP20 molecules takes place within a few μs after the pulse. The dissociation rate constant for the last CP20 ligand is (8 ± 1) × 103 S-1. The observation of a dissociation illustrates that, under dilute conditions, iron(II) is not fully complexed by CP20 and could potentially participate in redox cycling to produce oxyradicals. The CO2 - radical does not reduce iron(III)(cp20)3, which indicates that this complex reacts, as expected, very slowly with inner-sphere reductants. Wiley-VCH Verlag GmbH & Co. KGaA, 2006).
Interaction between the low molecular mass components of blood serum and the VO(IV)-DHP system (DHP = 1,2-dimethyl-3-hydroxy-4(1H)-pyridinone)
Buglyo, Peter,Kiss, Tamas,Kiss, Erzsebet,Sanna, Daniele,Garribba, Eugenio,Micera, Giovanni
, p. 2275 - 2282 (2002)
In order to estimate the impact of the low molecular mass (l.m.m.) VO(IV) binders of blood serum on the potentially insulin-enhancing drug [VO(DHP)2] [DHP = 1,2-dimethyl-3-hydroxy-4(1H)-pyridinone], the speciation in the binary system VO(IV)-DHP and in the ternary systems VO-DHP-ligand B (B = oxalate, lactate, citrate or phosphate) was studied by pH-potentiometry at 25.0°C and at an ionic strength I = 0.2 mol dm-3 (KCl). The binding modes of the complexes formed were determined by spectroscopic (electronic absorption and EPR) techniques. DHP was found to form stable mono and bis complexes via the coordination of (O,O) chelate(s). Through displacement of the oxo group of VO(IV), the tris complex is also formed, especially at a high excess of ligand. The results in the ternary systems demonstrate that, at physiological pH, none of the B ligands can compete with DHP; [VO(DHP)2] therefore seems to remain almost completely intact, even in the presence of citrate, the strongest competitor among these B ligands. These findings indicate that, for DHP, unlike maltol or picolinic acid, ternary complex formation and thus transformation reactions with the l.m.m. binders of biofluids, is almost negligible. From among the three carrier molecules, only DHP can effeciently compete with serum transferrin for binding of VO(IV).
Synthesis, Modification, and Biological Evaluation of a Library of Novel Water-Soluble Thiopyridone-Based Organometallic Complexes and Their Unexpected (Biological) Behavior
Gajic, Natalie,Happl, Barbara,Harringer, Sophia,Hejl, Michaela,Jakupec, Michael A.,Kandioller, Wolfgang,Kast, Caroline,Keppler, Bernhard K.,Koellensperger, Gunda,Legin, Anton A.,Ozenil, Marius,Roller, Alexander,Schweikert, Andreas,Wernitznig, Debora
, (2020/04/20)
A series of 16 dinuclear thiopyridone-based organometallics with excellent water solubility, increased stability and remarkable cytotoxicity were synthesized and characterized. The complexes of this work formed dimeric species featuring a double positive charge in polar protic solvents, accounting for their outstanding solubility in aqueous solution. Most of them displayed higher antiproliferative activity than their parental thiomaltol complex, with unexpected cytotoxicity trends depending on the employed metal center, ligand modification, and cell line. Insights into their behavior in biological systems were gathered by means of amino-acid interaction studies, cytotoxicity tests in 3D spheroid models, laser ablation, cellular accumulation measurements, as well as cell cycle experiments.
Application of 1-aryl-4-pyridone compound
-
Paragraph 0071-0074, (2020/01/12)
The invention discloses application of a 1-aryl-4-pyridone compound, and provides application of a compound of a structure of a formula (I) shown in the description in inhibiting activity of plant pathogenic bacteria. The compound of the structure of the formula (I) shown in the description has outstanding broad-spectrum antifungal activity upon plant pathogenic bacteria in agricultural production, and meanwhile, has a prevention and treatment effect on bacterial disease of crops. In-vivo biological assay shows that the compound of the structure of the formula (I) shown in the description hasa prevention and control effect greater than 95% on cucumber downy mildew, cucumber target leaf spot, wheat scab and tomato gray mold. Meanwhile, results of postharvest fresh-keeping tests of mangos show that the compound is capable of effectively controlling postharvest diseases of mangos and in addition, prolonging the fresh-keeping time of the mangos. In addition, results show that the compoundis also capable of effectively controlling bacterial leaf blight of rice in pot experiments, and is more effective than a commercial fungicide zhongshengmycin. In conclusion, the 1-aryl-4-pyridone derivative of the formula (I) shown in the description has broad-spectrum plant pathogenic fungus resistance and bacterial activity, and is a type of lead compounds with wide bioactivity.